Skip to content
Study details
Enrolling now

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

AstraZeneca
NCT IDNCT07276581ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

320

Study length

about 2.7 years

Ages

18+

Locations

25 sites in AZ, CA, CO +9

What this study is about

This trial is testing a treatment called AZD1163 for people with rheumatoid arthritis. The goal is to see if this treatment helps improve symptoms and is safe.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Placebo
  • 2.Take AZD1163

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Change From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12

Secondary: Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12, Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12, Summary statistics to evaluate the PK of AZD1163

Body systems

Immune